Yüklüyor......
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
The maximum tolerated dose of the panobinostat and carfilzomib combination in patients with relapsed/refractory multiple myeloma (RRMM) was not reached in our previous dose‐escalation study. We report additional dose levels in the phase I/II, single‐arm, multicenter, standard 3 + 3 dose‐escalation e...
Kaydedildi:
| Yayımlandı: | Am J Hematol |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley & Sons, Inc.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7986798/ https://ncbi.nlm.nih.gov/pubmed/33421178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26088 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|